Oestrogen Inhibition Reverses PAH and Associated Metabolic Defects

erj.ersjournals.com
oestrogen-inhibition-reverses-pah-and-associated-metabolic-defects

Increased oestrogen is a strong epidemiological risk factor for development of pulmonary arterial hypertension (PAH) in patients, associated with metabolic defects. In addition, oestrogens drive penetrance in mice carrying mutations in bone morphogenetic protein receptor type II (BMPR2), the cause of most heritable PAH. The goal of the present study was to determine whether inhibition of oestrogens was effective in the treatment of PAH in these mice.

Read More